Literature DB >> 1748551

Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma.

B R Ksander1, P E Rubsamen, K R Olsen, S W Cousins, J W Streilein.   

Abstract

Cell suspensions prepared enzymatically from an ocular choroidal melanoma were cultured in vitro in an effort to generate (1) melanoma tumor cell lines and (2) tumor-infiltrating lymphocytes cytotoxic for ocular melanoma cells. Even though histologic study of the tumor did not show "significant" infiltrating bone marrow-derived cells, lymphocytes were generated readily in cultures to which interleukin-2 was added. Phenotypic analysis of the cultured lymphocytes indicated that T-cells, natural killer (NK) cells, and lymphokine-activated killer (LAK) cells were present. Moreover, functional studies of the cultured lymphocytes revealed NK activity, LAK activity, and most importantly, tumor antigen-specific cytotoxic T-cell activity. It was concluded that it is possible to obtain tumor cell lines and tumor-infiltrating lymphocytes from ocular tumors, both of which would be required if cellular immunotherapy of ocular tumors is contemplated. In addition, these results indicate that ocular melanomas can express unique tumor-specific antigens and that the immune system of a patient with such an ocular tumor can perceive these tumor antigens because antigen-specific precursor cytotoxic T-cells were present in the tumor-containing eye at the time of enucleation. The theoretic and therapeutic implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748551

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  29 in total

1.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

2.  Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a.

Authors:  Hima Anbunathan; Ruth Verstraten; Arun D Singh; J William Harbour; Anne M Bowcock
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

4.  Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Ahmad Al-Moujahed; Fotini Nicolaou; Katarzyna Brodowska; Thanos D Papakostas; Anna Marmalidou; Bruce R Ksander; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

Review 5.  Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).

Authors:  Martine J Jager; J Antonio Bermudez Magner; Bruce R Ksander; Sander R Dubovy
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

6.  Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.

Authors:  Jennifer Carlring; Munitta Shaif-Muthana; Karen Sisley; Ian G Rennie; Anna K Murray
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

7.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

8.  Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease.

Authors:  P W Chen; T G Murray; T Uno; M L Salgaller; R Reddy; B R Ksander
Journal:  Clin Exp Metastasis       Date:  1997-09       Impact factor: 5.150

9.  Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients.

Authors:  X Q Huang; M S Mitchell; P E Liggett; A L Murphree; J Kan-Mitchell
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

10.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.